FORM 6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of February, 2023

Commission File Number 000-29962

Kazia Therapeutics Limited

(Translation of registrant’s name into English)

Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☑ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

On February 28, 2023, Kazia Therapeutics Limited (the “Company”) filed its unaudited half-year results for the six months ended December 31, 2022, with the Australian Securities Exchange, a copy of which is attached to this Form 6-K as Exhibit 99.1.

On February 28, 2023, the Company issued an ASX announcement titled, “Proceeds of Capital Raise and Share Purchase Plan.” A copy of this release is attached hereto as Exhibit 99.2 and is incorporated herein by reference.

On February 28, 2023, the Company issued an ASX announcement titled, “Resignation of Company Secretary and Appointment of New Company Secretary.” A copy of this release is attached hereto as Exhibit 99.3 and is incorporated herein by reference.

The Company hereby incorporates by reference the information contained herein, including Exhibits 99.1, 99.2 and 99.3, except for the quotes of Iain Ross contained in Exhibit 99.2, into the Company’s registration statement on Form F-3 (File No. 333-259224).

EXHIBIT LIST


Exhibit		Description

99.1		Half-year report for the six months ended December 31, 2022

99.2		ASX Announcement of Kazia Therapeutics Limited dated February 28, 2023

99.3		ASX Announcement of Kazia Therapeutics Limited dated February 28, 2023

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Kazia Therapeutics Limited (Registrant)

/s/ Karen Krumeich

Karen Krumeich

Chief Financial Officer

Date: February 28, 2023